학술논문

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Document Type
Article
Source
In: The Lancet Oncology. (The Lancet Oncology, October 2023, 24(10):1094-1108)
Subject
Language
English
ISSN
14745488
14702045